sur ABIVAX (EPA:ABVX)
Abivax unveils its objectives for 2026
The biotechnology company Abivax is projecting significant progress in 2026, focused on the development of its drug candidate, obefazimod. Obefazimod is currently in advanced clinical trials for the treatment of ulcerative colitis (UC). Market research predicts strong growth in this sector, potentially positioning obefazimod as a market leader.
Results from the ABTECT-UC trial, focused on UC, are expected by mid-2026, while the ENHANCE-CD study for Crohn's disease will unveil its first results by the end of 2026. In parallel, Abivax is presenting 22 abstracts at the ECCO congress, emphasizing the effect of obefazimod.
The company's financial visibility is assured until 2027, following the repayment of its debt. Abivax plans to submit a marketing authorization application in the United States at the end of 2026.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABIVAX